Combination brentuximab vedotin and bendamustine for pediatric patients with relapsed/refractory Hodgkin lymphoma

In patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL), achieving a complete metabolic response (CMR) after salvage therapy is associated with superior outcomes, and optimal treatments must be identified. The combination of brentuximab vedotin and bendamustine (BVB), although highly active...

Descripción completa

Detalles Bibliográficos
Autores principales: Forlenza, Christopher J., Gulati, Nitya, Mauguen, Audrey, Absalon, Michael J., Castellino, Sharon M., Franklin, Anna, Keller, Frank G., Shukla, Neerav
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2021
Materias:
Lymphoid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714712/
https://www.ncbi.nlm.nih.gov/pubmed/34559223
http://dx.doi.org/10.1182/bloodadvances.2021005268

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714712/
https://www.ncbi.nlm.nih.gov/pubmed/34559223
http://dx.doi.org/10.1182/bloodadvances.2021005268

Ejemplares similares